Gene Therapy for Leber Congenital Amaurosis

(RDH12 Trial)

This trial explores a new gene therapy, OPGx-RDH12-1001, designed to help individuals with Leber Congenital Amaurosis (LCA), a rare eye condition causing severe vision loss due to a specific genetic mutation. The treatment involves a one-time injection into the retina of the eye with worse vision. Researchers aim to assess the safety and effectiveness of this therapy by testing it at two different dose levels. Individuals with LCA who have the RDH12 mutation and significant vision loss may qualify for participation. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial does not specify if you must stop taking your current medications. However, you cannot participate if you are on continuous systemic immunosuppressive therapy, have used investigational drugs recently, or are currently using medications that are potentially neuroprotective or retinotoxic.

Research has shown that gene therapies like OPGx-RDH12, currently under testing for Leber Congenital Amaurosis, are usually well-tolerated. This treatment resembles other approved gene therapies, such as Luxturna, which have proven safe. Although specific data on OPGx-RDH12 is not yet available, the study includes a carefully designed independent monitoring committee to ensure safety. In similar gene therapy trials, side effects are rare and generally mild, such as temporary eye irritation. The trial uses small, cautious groups to maintain a safe approach.¹²³⁴⁵

Unlike other treatments for Leber Congenital Amaurosis, which often focus on managing symptoms, OPGx-RDH12 leverages gene therapy to address the root cause of the disease. It uses an adeno-associated virus (AAV) to deliver a healthy copy of the RDH12 gene directly into the retina. This approach aims to restore visual function by tackling the genetic defect at its source, offering the potential for more lasting improvements in vision. Researchers are excited about this treatment because it represents a shift from symptom management to potential disease modification, providing hope for a more effective and long-term solution.

Research has shown that the gene therapy OPGx-RDH12, tested in this trial, could be promising for treating Leber Congenital Amaurosis (LCA) caused by RDH12 mutations. In early animal studies, this therapy restored the retina's function and structure. Similar treatments, like Luxturna, have already succeeded in treating different genetic eye conditions. These therapies deliver a healthy version of the gene directly to the retina to improve vision. Early results from related treatments, such as OPGx-LCA5, demonstrated vision improvements in both adults and children with LCA. This offers hope that OPGx-RDH12 might provide similar benefits for people with RDH12-related LCA.¹²³⁴⁶